Improving the economics of downstream processing of AAV vectors through novel capture resins and improved processes to increase yield of infectious particles

目前可用于AAV衣壳捕获和纯化的工具是基于为单克隆抗体生产开发的技术，并且通常没有针对病毒载体进行优化。可用于AAV捕获的大多数方法采用使用抗体配体技术的亲和层析。阿斯特雷亚是一家总部位于英国的SME公司，在成功开发以生物分子分离为目标的亲和吸附剂方面有30多年的历史。与NRC的合作将集中在开发更具成本效益的，强大的，可扩展的AAV颗粒分离方法，使用新的色谱技术。NRC在生产AAV病毒载体以及相关的检测技术和纯化方法方面具有丰富的经验，阿斯特雷亚在开发稳健有效的色谱吸附剂和下游工艺方面具有丰富的经验。合作将为双方带来利益，并使英国和加拿大成为先进生物疗法改进制造工艺的领先开发商。

The current tools available for AAV capsid capture and purification have been based on technologies developed for monoclonal antibodies production, and in general are not optimized for viral vectors. The majority of methods available for AAV capture employ affinity chromatography using antibody ligand technology. These products are costly and are not adapted for high yield of quality capsids.Astrea is a UK based SME company with over 30 years history of successful development of affinity adsorbents targeting the separation of biomolecules. A collaboration with the NRC would focus on the development of more cost effective, robust, and scalable AAV particle separation methods, using novel chromatography techniques. The NRC has significant experience in producing AAV viral vectors together with associated assay techniques and purification methodologies, and Astrea has significant experience in the development of robust and effective chromatography adsorbents and downstream processes. Collaboration will provide benefit to both parties and place the UK and Canada as leading developers of improved manufacturing processes for advance biotherapies